Literature DB >> 19261608

Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Isao Hirano1, Satoki Nakamura, Daisuke Yokota, Takaaki Ono, Kazuyuki Shigeno, Shinya Fujisawa, Kaori Shinjo, Kazunori Ohnishi.   

Abstract

The constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway commonly occurs in cancers and is a crucial event in tumorigenesis. Chronic myelogenous leukemia (CML) is characterized by a reciprocal chromosomal translocation (9;22) that generates the Bcr-Abl fusion gene. The PI3K/Akt pathway is activated by Bcr-Abl chimera protein and mediates the leukemogenesis in CML. However, the mechanism by which Bcr-Abl activates the PI3K/Akt pathway is not completely understood. In the present study, we found that pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 (PHLPP1 and PHLPP2) were depleted in CML cells. We investigated the interaction between PHLPPs and Bcr-Abl in CML cell lines and Bcr-Abl+ progenitor cells from CML patients. The Abl kinase inhibitors and depletion of Bcr-Abl induced the expression of PHLPP1 and PHLPP2, which dephosphorylated Ser-473 on Akt1, -2, and -3, resulting in inhibited proliferation of CML cells. The reduction of PHLPP1 and PHLPP2 expression by short interfering RNA in CML cells weakened the Abl kinase inhibitor-mediated inhibition of proliferation. In colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte; colony-forming unit-granulocyte, macrophage; and burst-forming unit-erythroid, treatment with the Abl kinase inhibitors and depletion of Bcr-Abl induced PHLPP1 and PHLPP2 expression and inhibited colony formation of Bcr-Abl+ progenitor cells, whereas depletion of PHLPP1 and PHLPP2 weakened the inhibition of colony formation activity by the Abl kinase inhibitors in Bcr-Abl+ progenitor cells. Thus, Bcr-Abl represses the expression of PHLPP1 and PHLPP2 and continuously activates Akt1, -2, and -3 via phosphorylation on Ser-473, resulting in the proliferation of CML cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261608      PMCID: PMC2755940          DOI: 10.1074/jbc.M808182200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Gene signals relapse of breast, ovarian cancers.

Authors:  J L Marx
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

Review 3.  The molecular genetics of Philadelphia chromosome-positive leukemias.

Authors:  R Kurzrock; J U Gutterman; M Talpaz
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

4.  Characterization of sporadic colon cancer by patterns of genomic instability.

Authors:  Ajay Goel; Christian N Arnold; Donna Niedzwiecki; Dong K Chang; Luigi Ricciardiello; John M Carethers; Jeannette M Dowell; Linda Wasserman; Carolyn Compton; Robert J Mayer; Monica M Bertagnolli; C Richard Boland
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

5.  Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.

Authors:  Shawn D Safford; Dominique Goyeau; Alex J Freemerman; Rex Bentley; Mary Lou Everett; Paul E Grundy; Michael A Skinner
Journal:  Ann Surg Oncol       Date:  2003-03       Impact factor: 5.344

6.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

7.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

8.  Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.

Authors:  Y Patael-Karasik; M Daniely; W H Gotlieb; G Ben-Baruch; J Schiby; G Barakai; B Goldman; A Aviram; E Friedman
Journal:  Cancer Genet Cytogenet       Date:  2000-08

9.  Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma.

Authors:  H Tsuda; W D Zhang; Y Shimosato; J Yokota; M Terada; T Sugimura; T Miyamura; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

10.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

Authors:  Agata Klejman; Lori Rushen; Andrea Morrione; Artur Slupianek; Tomasz Skorski
Journal:  Oncogene       Date:  2002-08-29       Impact factor: 9.867

View more
  12 in total

Review 1.  Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.

Authors:  Priyanka Singh; Veerandra Kumar; Sonu Kumar Gupta; Gudia Kumari; Malkhey Verma
Journal:  Med Oncol       Date:  2021-01-16       Impact factor: 3.064

Review 2.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

3.  PHLPP1 splice variants differentially regulate AKT and PKCα signaling in hippocampal neurons: characterization of PHLPP proteins in the adult hippocampus.

Authors:  Travis C Jackson; Jonathan D Verrier; Susan Semple-Rowland; Ashok Kumar; Thomas C Foster
Journal:  J Neurochem       Date:  2010-09-28       Impact factor: 5.372

4.  Guide to virtual screening: application to the Akt phosphatase PHLPP.

Authors:  William Sinko; Emma Sierecki; César A F de Oliveira; J Andrew McCammon
Journal:  Methods Mol Biol       Date:  2012

5.  mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.

Authors:  Jianyu Liu; Payton D Stevens; Tianyan Gao
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

6.  PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.

Authors:  Shuai Wang; Huibo Wang; Ben C Davis; Jiyong Liang; Rutao Cui; Sai-Juan Chen; Zhi-Xiang Xu
Journal:  Biochem Biophys Res Commun       Date:  2011-07-29       Impact factor: 3.575

Review 7.  Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy.

Authors:  D J Roberts; S Miyamoto
Journal:  Cell Death Differ       Date:  2014-10-17       Impact factor: 15.828

8.  Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3β/Fyn kinase axis during oxidative hepatocellular toxicity.

Authors:  F Rizvi; S Shukla; P Kakkar
Journal:  Cell Death Dis       Date:  2014-03-27       Impact factor: 8.469

Review 9.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 10.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.